Factors associated with anticholinergic-induced oral-buccal-lingual dyskinesia in Parkinson's disease.
作者信息
Ha Joonyoung, Kang Suk Yun, Baik Kyoungwon, Sohn Young H, Lee Phil Hyu, Baek Min Seok, Hong Jin Yong
机构信息
Department of Neurology, Yonsei University Wonju College of Medicine, Wonju, Korea.
Department of Neurology, Dongtan Sacred Heart Hospital, Hallym University College of Medicine, Hwaseong, Korea.
出版信息
J Mov Disord. 2024 Jan;17(1):109-111. doi: 10.14802/jmd.23069. Epub 2023 Sep 22.
Abstract
摘要
相似文献
1
Factors associated with anticholinergic-induced oral-buccal-lingual dyskinesia in Parkinson's disease.帕金森病中与抗胆碱能药物诱发的口腔-颊-舌运动障碍相关的因素。
J Mov Disord. 2024 Jan;17(1):109-111. doi: 10.14802/jmd.23069. Epub 2023 Sep 22.
2
Orobuccal dyskinesia associated with trihexyphenidyl therapy in a patient with Parkinson's disease.一名帕金森病患者使用苯海索治疗后出现口颊部运动障碍。
Mov Disord. 1993 Oct;8(4):512-4. doi: 10.1002/mds.870080417.
3
Eltoprazine counteracts l-DOPA-induced dyskinesias in Parkinson's disease: a dose-finding study.依托必利可对抗帕金森病中左旋多巴诱导的运动障碍：一项剂量探索研究。
Brain. 2015 Apr;138(Pt 4):963-73. doi: 10.1093/brain/awu409. Epub 2015 Feb 10.
4
White matter alterations in Parkinson's disease with levodopa-induced dyskinesia.帕金森病伴左旋多巴诱导运动障碍的白质改变。
Parkinsonism Relat Disord. 2021 Sep;90:8-14. doi: 10.1016/j.parkreldis.2021.07.021. Epub 2021 Jul 24.
5
Serum sodium and chloride are inversely associated with dyskinesia in Parkinson's disease patients.血清钠和氯与帕金森病患者的运动障碍呈负相关。
Brain Behav. 2017 Nov 9;7(12):e00867. doi: 10.1002/brb3.867. eCollection 2017 Dec.
6
Does Late Levodopa Administration Delay the Development of Dyskinesia in Patients with De Novo Parkinson's Disease?左旋多巴晚期给药是否会延迟新发帕金森病患者运动障碍的发展？
CNS Drugs. 2018 Oct;32(10):971-979. doi: 10.1007/s40263-018-0549-x.
7
Ropinirole versus L-DOPA effects on striatal opioid peptide precursors in a rodent model of Parkinson's disease: implications for dyskinesia.在帕金森病啮齿动物模型中，罗匹尼罗与左旋多巴对纹状体阿片肽前体的影响：对运动障碍的影响
Exp Neurol. 2004 Jan;185(1):36-46. doi: 10.1016/j.expneurol.2003.09.001.
8
Age of Parkinson's disease onset as a predictor for the development of dyskinesia.帕金森病发病年龄可预测运动障碍的发生。
Mov Disord. 2010 Jul 15;25(9):1177-82. doi: 10.1002/mds.23068.
9
GABA storage and release in the medial globus pallidus in L-DOPA-induced dyskinesia priming.在 L-DOPA 诱导的运动障碍预备期内，内侧苍白球中的 GABA 储存和释放。
Neurobiol Dis. 2020 Sep;143:104979. doi: 10.1016/j.nbd.2020.104979. Epub 2020 Jun 24.
10
Association between Anticholinergic Medication Use and Risk of Dementia among Patients with Parkinson's Disease.抗胆碱能药物的使用与帕金森病患者痴呆风险的关系。
Pharmacotherapy. 2019 Aug;39(8):798-808. doi: 10.1002/phar.2305. Epub 2019 Jul 17.
本文引用的文献
1
Tardive dyskinesia: Out of the shadows.迟发性运动障碍：走出阴影。
J Neurol Sci. 2018 Jun 15;389:1-3. doi: 10.1016/j.jns.2018.02.009. Epub 2018 Feb 5.
2
Anticholinergic agents can induce oromandibular dyskinesia.抗胆碱能药物可引起口颌运动障碍。
J Mov Disord. 2009 Oct;2(2):69-71. doi: 10.14802/jmd.09018. Epub 2009 Oct 30.
3
Factors predictive of the development of Levodopa-induced dyskinesia and wearing-off in Parkinson's disease.帕金森病中左旋多巴诱导的运动障碍和开-关现象发展的预测因素。
Mov Disord. 2013 Jul;28(8):1064-71. doi: 10.1002/mds.25364. Epub 2013 Apr 29.
4
Orobuccal dyskinesia associated with trihexyphenidyl therapy in a patient with Parkinson's disease.一名帕金森病患者使用苯海索治疗后出现口颊部运动障碍。
Mov Disord. 1993 Oct;8(4):512-4. doi: 10.1002/mds.870080417.
5
Effect of anticholinergics on tardive dyskinesia. A controlled discontinuation study.抗胆碱能药物对迟发性运动障碍的影响。一项对照停药研究。
Br J Psychiatry. 1984 Sep;145:304-10. doi: 10.1192/bjp.145.3.304.
6
Abnormal involuntary movements induced by anticholinergic therapy.抗胆碱能治疗引起的异常不自主运动。
Acta Neurol Scand. 1974;50(6):801-11. doi: 10.1111/j.1600-0404.1974.tb02820.x.
Zotero 插件